Belvedere Trading
AVDL

Belvedere Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Belvedere Trading’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,500
Closed -$10.7K – 936
2022
Q4 		$10.7K Buy
+1,500
New +$10.5K ﹤0.01% 901

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Belvedere Trading's AVDL Position: Q1 2022 in Review

Belvedere Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2022, closing a stake of 3,881 shares — an estimated $22K sold.

Belvedere Trading first reported a position in AVDL in Q3 2021 and held it in 2 quarters. The position peaked at $86K in Q3 2021. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2022.

  • Belvedere Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Belvedere Trading sold 3,881 Avadel Pharmaceuticals shares in Q1 2022, an estimated $22K.
  • Belvedere Trading first reported a position in Avadel Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Belvedere Trading's Avadel Pharmaceuticals position peaked at $86K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.